Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzyme replacement therapy in children and adults with Pompe disease
NL-OMON60102Phase 4Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2007
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alglucosidase alfa in Pompe disease, sponsored by Erasmus MC. Primary endpoints: Survival, Muscle strength and function and 7 more. Planned start Jun 2007; status: not yet recruiting.
02
Drugs
alglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NL-OMON60102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60102.